Korea Advanced Institute of Science and Technology

Yonsei University

Biotrion Co., Ltd.

Mvrix Co., Ltd.

Osteoneurogen Inc.

Dandi Bioscience Inc

Inthera, Inc.

Protheon Co., Ltd.

Baik Lin Seong

Young Ho Byun

Moon H Han

Yo Han Jang

Kwang Hee Lee

Chul Woo Kim

Han Soo Kim

Hye Min Lee

Ho Sup Yoon

Byung Soo Youn

Dae-Hyuk Kweon

Ik Hwan Kim

Yeong-Min Park

Sang-Uk Seo

Byoungjae Kong

Moon Kee Maeng

Woo-Jae Chung

Sukchan Lee

Min Ju Ham

Sang Uk Seo

Deog Young Choi

Kyoung Sim Han

Byung Hee Kim

Hyeong Deok Choi

Seong-Il Choi

Eun Sook Park

Hang Cheol Shin

Tae-Ick Mheen

Kyun-Hwan Kim

Ki-Sun Ryu

Hyeung-Jin Son

The present invention relates to a novel peptide or a partial sequence thereof for enhancing expression efficiency of a target protein, and a fusion protein comprising the same. The novel peptide according to the present invention can enhance expression efficiency of a target protein, and furthermore, the peptide can also be applied to a solubility-enhancing fusion protein in order to enhance solubility of the target protein, so that solubility as well as expression efficiency of the target protein is enhanced, which allows such a peptide to be usefully used for production of a recombinant target protein.

Peptide for enhancing expression efficiency of target protein, and fusion protein comprising same

The present invention relates to a nanoperforator having a lipid-bilayer nanodisc and a membrane-structured protein surrounding the nanodisc and to a pharmaceutical composition having the nanoperforator as an active ingredient for preventing or treating viral infectious diseases. The use of the lipid-bilayer nanoperforator provided in the present invention can lead to the safe prevention or treatment of a disease caused by viral infection regardless of whether the virus is a variant or not, and thus the present invention can be widely used for the safe and effective treatment of viral infectious diseases.

Pharmaceutical composition comprising nanoperforator for preventing or treating viral infectious diseases

The present invention relates to an anti-inflammatory composition, and more particularly to an anti-inflammatory composition containing, as an active ingredient, a compound represented by Formula 1 or a salt thereof, wherein the anti-inflammatory composition may inhibit inflammatory response even at an early stage by inhibiting the interaction between CD14 and LPS and blocking the expression of CD14 and the expression of TNF&#x3b1; and IL-1&#x3b2;, which are the key factors in inflammatory response, and may also regulate the expression of important factors, such as CCL2 (MCP-1), CCL7 (MCP-3), CXCL2, CHOP and NOX1, which are involved in inflammatory response.

Anti-inflammatory composition

Provided are a marker for detecting a highly pathogenic influenza virus including a protein mutant prepared by substituting the amino acids 68 and 69 of a PB1-F2 protein, a composition for detecting a highly pathogenic virus including an agent for measuring the protein mutant, and a detection kit including the same, a method for detecting a highly pathogenic virus including measuring the protein mutant, an antiviral composition against influenza A virus including an inhibitor of binding between a PB1-F2 protein in which the amino acids 68 and 69 are substituted and DDX3, and a method for screening an antiviral substance against influenza A virus.

Marker for detecting highly pathogenic influenza virus and use thereof

Disclosed is a universal influenza vaccine composition and corresponding methods comprising at least one attenuated live-attenuated influenza vaccine. The vaccine composition can exhibit a cross-protective effect against a wide range of influenza viruses and can ensure a strong protection efficacy, a wide range of protection, and safety. In addition, a vaccination method of heterologous live vaccines of the present invention induces various immunological effects so that cross-immunogenicity and cross-protective ability are remarkably increased, and thus is expected to be usefully utilized as a universal influenza prevention method. A person who has a basal immunity through infection with an influenza virus or vaccination with an influenza vaccine can be regarded as being in a state where primary vaccination has already been performed, single vaccination with a live vaccine induces an enhanced cross-immune response, and thus it is possible to expect a wide range of protective effects against various viruses.

Universal influenza vaccine using cold-adapted live-attenuated virus

Disclosed is an attenuation method of an influenza virus, that is, a reassortant virus and a preparation method thereof. The disclosed reassortant virus has, in a ratio of 6:2, genes encoding a recombinant non-toxic protein and a wild type non-toxic protein, and genes encoding toxic proteins, HA (hemagglutinin) and NA (neuraminidase), of an influenza virus, the recombinant non-toxic protein consisting of a substituted caspase recognition sequence without a change of a protein size within the wild type non-toxic protein of the influenza virus. The disclosed attenuated influenza virus shows a high attenuation without a reduction of productivity in a fertilized egg. Accordingly, the method can be used as an economically efficient live vaccine preparation method which has both safety and efficiency and can use a fertilized egg as a production system. Also, since a protein is not removed or modified during attenuation, the method can be used in combination with a conventional attenuated vaccine preparation technology such as cold-adaptation.

Method of preparing live viral vaccines by genetic engineering of viral genome

The present invention relates to an isolated attenuated influenza virus strain and a live vaccine comprising the same. The isolated attenuated influenza virus strain is prepared by cold-adaptation of a mother strain which carries 6 internal genomes of A/PR/8/34(H1N1) and two surface antigens HA and NA of A/Aichi/2/68(H3N2). The attenuated influenza virus strain and the live vaccine of the present invention are useful for prevention of seasonal influenza episodes and sudden outbreak of influenza pandemics of predicted or unknown identity, since they have safety, efficacy, high production yield, immediate protection against variety of influenza subtypes and prolonged protection against specific influenza subtype.

Attenuated influenza virus and a live vaccine comprising the same

Disclosed is a method for improving folding efficiency and solubility of a target protein linked to a RNA-binding protein by using RNA molecule as a molecular chaperone, wherein the RNA molecule interacts with the RNA-binding protein. More particularly, the present invention discloses method for improving folding efficiency and solubility of a target protein by transformation of a host cell with a expression vector comprising a polynucleotide encoding the target protein linked to an RNA-binding protein; culturing the transformed host cell in an appropriate culture medium under the condition that an RNA molecule either resident inside the host cell or provided by cotransformation of the host cell with polynucleotide encoding the RNA molecule interacts with the RNA-binding protein; and purifying the soluble protein from host cell lysate. The method of the present invention is very useful for production of soluble proteins for therapeutic, prophylactic and diagnostic applications.

Method for improving solubility and folding efficiency of target proteins using RNA as molecular chaperone

A biological process for converting rifamycin B to rifamycin O, rifamycin S or rifamycin SV by treatment with the whole cell, the cell extract, or the immobilized enzyme of Humicola spp. (ATCC 20620) or Monocillium spp. (ATCC 20621) is provided. The process also includes the recovery of rifamycin B in the fermentation broth after conversion to rifamycin O, rifamycin S or rifamycin SV.

Biological process for the preparation of rifamycin derivatives

3-Dialkylaminomethyl derivatives of rifamycin S is provided by reacting rifamycin S with an iminium salt in an organic solvent. This compound is converted to 3-dialkylaminomethyl derivatives by virtue of ascorbic acid.

Process for preparing rifamycin derivatives

Growing community of inventors

Seoul, South Korea

Baik Lin Seong